文献速递肿瘤 PET/CT核素与放射性配体治疗

非肿瘤肝组织能否作为结直肠癌肝转移患者单叶90Y玻璃微球放射栓塞后[18F]FDG-PET-CT的可靠参考指标

Can non-tumorous liver tissue serve as a reliable reference measure for [18F]FDG-PET-CT after unilobar 90Y glass radioembolization in patients with colorectal liver metastases?
PubMed 文献 · EJNMMI Res · 2025-09-26

该研究纳入18例结直肠癌肝转移患者,评估单叶90Y玻璃微球放射栓塞后治疗侧与未治疗侧非肿瘤肝组织的瘦体重校正平均标准化摄取值(SULmean)变化。治疗后治疗侧中位SULmean由基线2.88升至2.98,未治疗侧由2.95降至2.88,治疗/未治疗比值由0.96升至1.00(p=0.147),作者认为非肿瘤肝组织本底SUL可作为放射栓塞后3个月代谢反应的可靠参考。

要点

  • 治疗侧非肿瘤肝中位SULmean由基线2.88升至治疗后2.98。
  • 未治疗侧非肿瘤肝中位SULmean由2.95降至2.88。
  • 治疗/未治疗肝SULmean比值由0.96升至1.00(p=0.147),前后相关性不显著。

核心结论

  • 结直肠癌肝转移患者行叶性90Y玻璃微球放射栓塞后3个月,治疗侧与未治疗侧非肿瘤肝组织[18F]FDG摄取均未见显著升高。
  • 作者认为这一非显著升高提示非肿瘤肝组织(治疗侧与未治疗侧)的本底SUL作为单叶放射栓塞后3个月代谢反应评估的参考是可靠且适当的。

研究设计与样本

  • 研究纳入18例接受单叶90Y玻璃微球放射栓塞的结直肠癌肝转移患者。
  • 评估治疗侧与未治疗侧非肿瘤肝组织瘦体重校正平均标准化摄取值(SULmean)的变化。

主要发现

  • 治疗侧非肿瘤肝中位SULmean由基线2.88(范围2.24–3.81)升至治疗后2.98(范围2.53–3.53)。
  • 未治疗侧非肿瘤肝中位SULmean由2.95(范围2.23–4.02)变为2.88(范围2.39–3.71)。
  • 治疗/未治疗肝SULmean比值中位数由0.96(范围0.77–1.23)变为1.00(范围0.88–1.26),p=0.147。
  • 放射栓塞前后该比值相关性不显著。
  • 非肿瘤肝[18F]FDG摄取与治疗侧或未治疗侧吸收剂量之间未见趋势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Effect of radiation on [18F]FDG-uptake in non-tumorous liver tissue after radioembolization is sparsely investigated, despite the liver being the most common reference for assessment of metabolic response (e.g., PET Response Criteria In Solid Tumors). The study aims to evaluate changes in mean standardized uptake value corrected for lean body mass in treated and untreated non-tumorous liver after unilobar radioembolization with 90Y-glass microspheres in patients with colorectal liver metastases. RESULTS: Eighteen patients were included. Median mean standardized uptake value corrected for lean body mass in the treated lobe increased from baseline 2.88 (range 2.24–3.81) to posttreatment 2.98 (range 2.53–3.53). In the untreated lobe, the median mean standardized uptake value corrected for lean body mass changed from 2.95 (range 2.23–4.02) to 2.88 (range 2.39–3.71), respectively. The median mean standardized uptake value corrected for lean body mass of the ratio treated/untreated liver changed from 0.96 (range .77–1.23) to 1.00 (range .88–1.26) after treatment (p = 0.147)). The correlation for the ratio (mean standardized uptake value corrected for lean body mass in treated liver divided by mean standardized uptake value corrected for lean body mass in untreated liver) before and after radioembolization was nonsignificant. No trend was seen between [18F]FDG-uptake and treated or untreated non-tumorous liver absorbed dose. CONCLUSIONS: This study shows no significant increase in [18F]FDG-uptake in both treated and untreated non-tumorous liver in patients with liver metastases of colorectal carcinoma, three months after lobar 90Y-glass microsphere radioembolization. This non-significant increase suggests that using background SUL in the non-tumorous liver (treated and untreated) is reliable and appropriate as a reference to assess metabolic response three months after unilobar radioembolization.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ho LS, Braat MNGJA, Bol G, et al. Can non-tumorous liver tissue serve as a reliable reference measure for [18F]FDG-PET-CT after unilobar 90Y glass radioembolization in patients with colorectal liver metastases? EJNMMI Res. 2025. PMID: 41003938. doi:10.1186/s13550-025-01320-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。